The FAIR ACT aims to expedite access to innovative rare disease therapies by establishing a reciprocal approval mechanism with trusted international.
The FAIR ACT, or Fast-tracking Approval for Innovative Rare disease therapies Act, seeks to accelerate patient access to innovative medicines and clinical trials for life-threatening diseases. It introduces a reciprocal approval mechanism with trusted international regulatory authorities, including the European Medicines Agency, the Medicines and Healthcare Products Regulatory Agency of the United Kingdom, and Health Canada. The bill allows for the approval of drugs already authorized for marketing in these countries, provided they meet certain criteria.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.